Display options
Share it on

Biomed Res Int. 2015;2015:584546. doi: 10.1155/2015/584546. Epub 2015 Mar 02.

Prediction of drug indications based on chemical interactions and chemical similarities.

BioMed research international

Guohua Huang, Yin Lu, Changhong Lu, Mingyue Zheng, Yu-Dong Cai

Affiliations

  1. Institute of Systems Biology, Shanghai University, Shanghai 200444, China ; Department of Mathematics, Shaoyang University, Shaoyang, Hunan 422000, China.
  2. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  3. Department of Mathematics, East China Normal University, Shanghai 200241, China.
  4. Institute of Systems Biology, Shanghai University, Shanghai 200444, China.

PMID: 25821813 PMCID: PMC4363546 DOI: 10.1155/2015/584546

Abstract

Discovering potential indications of novel or approved drugs is a key step in drug development. Previous computational approaches could be categorized into disease-centric and drug-centric based on the starting point of the issues or small-scaled application and large-scale application according to the diversity of the datasets. Here, a classifier has been constructed to predict the indications of a drug based on the assumption that interactive/associated drugs or drugs with similar structures are more likely to target the same diseases using a large drug indication dataset. To examine the classifier, it was conducted on a dataset with 1,573 drugs retrieved from Comprehensive Medicinal Chemistry database for five times, evaluated by 5-fold cross-validation, yielding five 1st order prediction accuracies that were all approximately 51.48%. Meanwhile, the model yielded an accuracy rate of 50.00% for the 1st order prediction by independent test on a dataset with 32 other drugs in which drug repositioning has been confirmed. Interestingly, some clinically repurposed drug indications that were not included in the datasets are successfully identified by our method. These results suggest that our method may become a useful tool to associate novel molecules with new indications or alternative indications with existing drugs.

References

  1. Postgrad Med. 2009 May;121(3 Suppl 1):25-30 - PubMed
  2. Lancet. 2004 May 29;363(9423):1802-11 - PubMed
  3. Nucleic Acids Res. 2000 Jan 1;28(1):27-30 - PubMed
  4. Bioinformatics. 2005 Jun;21 Suppl 1:i38-46 - PubMed
  5. J Theor Biol. 2010 Mar 21;263(2):203-9 - PubMed
  6. J Med Chem. 2002 Sep 12;45(19):4350-8 - PubMed
  7. Expert Rev Proteomics. 2011 Jun;8(3):391-404 - PubMed
  8. Blood. 2009 Jan 29;113(5):1002-5 - PubMed
  9. Exp Brain Res. 2003 Feb;148(4):521-4 - PubMed
  10. Clin Cancer Res. 2001 Apr;7(4):800-5 - PubMed
  11. Nucleic Acids Res. 2008 Jan;36(Database issue):D684-8 - PubMed
  12. Mol Syst Biol. 2011;7:496 - PubMed
  13. PLoS Comput Biol. 2012;8(5):e1002503 - PubMed
  14. Bioinformatics. 2005 Jun;21 Suppl 1:i359-68 - PubMed
  15. Mol Biosyst. 2014 Apr;10(4):868-77 - PubMed
  16. Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W55-9 - PubMed
  17. Bioinformatics. 2004 Feb 12;20(3):421-3 - PubMed
  18. PLoS Comput Biol. 2009 Jul;5(7):e1000450 - PubMed
  19. PLoS One. 2012;7(4):e35254 - PubMed
  20. BMC Bioinformatics. 2005;6:272 - PubMed
  21. Lancet. 2010 Dec 11;376(9757):1989-99 - PubMed
  22. Target Oncol. 2011 Jun;6(2):69-94 - PubMed
  23. J Theor Biol. 2009 Mar 7;257(1):17-26 - PubMed
  24. Semin Hematol. 2001 Oct;38(4 Suppl 10):4-8 - PubMed
  25. Bioinformatics. 2006 Mar 15;22(6):645-50 - PubMed
  26. Eur J Clin Invest. 2008 Jan;38(1):43-52 - PubMed
  27. Clin Pharmacol Ther. 2009 Nov;86(5):507-10 - PubMed
  28. PLoS One. 2014;9(9):e107767 - PubMed
  29. J Chem Inf Comput Sci. 2002 Nov-Dec;42(6):1273-80 - PubMed
  30. Bioinformatics. 2001 Aug;17(8):721-8 - PubMed
  31. J Theor Biol. 2009 May 21;258(2):289-93 - PubMed
  32. N Engl J Med. 2009 Feb 12;360(7):679-91 - PubMed
  33. Bioinformatics. 2010 Jun 15;26(12):i246-54 - PubMed
  34. Cancer Res. 2010 Mar 15;70(6):2146-57 - PubMed
  35. ChemMedChem. 2006 Oct;1(10):1066-8 - PubMed
  36. Eur J Cardiovasc Prev Rehabil. 2009 Feb;16(1):1-9 - PubMed
  37. PLoS One. 2013;8(2):e56517 - PubMed
  38. Nat Rev Drug Discov. 2004 Aug;3(8):673-83 - PubMed
  39. J Am Med Assoc. 1956 Feb 4;160(5):376-85 - PubMed
  40. Nature. 2007 Aug 9;448(7154):645-6 - PubMed
  41. Eur Neuropsychopharmacol. 1996;6 Suppl 2:S3-5 - PubMed
  42. J Postgrad Med. 2011 Apr-Jun;57(2):153-60 - PubMed
  43. PLoS One. 2011;6(12):e29491 - PubMed
  44. Bioinformatics. 2003 Sep 1;19(13):1656-63 - PubMed
  45. PLoS One. 2012;7(8):e43927 - PubMed
  46. Trends Pharmacol Sci. 2013 Sep;34(9):508-17 - PubMed
  47. J Chem Inf Model. 2010 May 24;50(5):742-54 - PubMed
  48. J Bioinform Comput Biol. 2010 Jun;8(3):593-606 - PubMed
  49. PLoS One. 2011;6(1):e14556 - PubMed
  50. Nat Rev Genet. 2006 Feb;7(2):119-29 - PubMed
  51. J Cheminform. 2011 Oct 07;3:33 - PubMed
  52. Blood. 2005 Mar 15;105(6):2527-34 - PubMed
  53. Science. 1989 Apr 7;244(4900):41-7 - PubMed
  54. Nat Chem Biol. 2008 Nov;4(11):682-90 - PubMed
  55. J Theor Biol. 2011 Jul 21;281(1):18-23 - PubMed
  56. Crit Rev Biochem Mol Biol. 1995;30(4):275-349 - PubMed
  57. Immunotherapy. 2010 Sep;2(5):637-50 - PubMed
  58. Nature. 2009 Nov 12;462(7270):175-81 - PubMed
  59. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6 - PubMed
  60. Nat Genet. 2000 May;25(1):25-9 - PubMed
  61. Curr Pharm Des. 2006;12(17):2111-20 - PubMed
  62. Brief Bioinform. 2011 Jul;12(4):303-11 - PubMed
  63. Biochem Pharmacol. 2002 Jun 15;63(12):2151-8 - PubMed
  64. Cancer Biol Ther. 2010 Sep 15;10(6):543-8 - PubMed
  65. Postgrad Med. 2010 May;122(3Suppl):1-8 - PubMed

MeSH terms

Publication Types